Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,304.90",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "1,304.90",
    "mcapval": "105,391.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "May 11",
    "curr_time": "",
    "bse_nse_vol": "14.33 lacs",
    "exc_status": "Active",
    "traded_date": "May 11, 2026",
    "traded_date_str": "2026 05 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cipla Ltd. Hits Intraday Low Amid Price Pressure on 11 May 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-hits-intraday-low-amid-price-pressure-on-11-may-2026-3985777",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CiplaLtd_priceRelatedfactors_3985777.png",
        "date": "2026-05-11 15:15:58",
        "description": "Cipla Ltd. experienced a notable decline today, touching an intraday low of Rs 1305.4, reflecting a 3.14% drop as the stock faced significant price pressure amid broader market weakness and sector underperformance."
      },
      {
        "title": "Cipla Ltd Sees Sharp Open Interest Surge Amidst Weak Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-sharp-open-interest-surge-amidst-weak-price-action-3985762",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CiplaLtd_oi_spurts_by_underlying_3985762.png",
        "date": "2026-05-11 15:00:08",
        "description": "Cipla Ltd., a leading large-cap pharmaceutical stock, has witnessed a notable 10.18% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in open interest, coupled with declining prices and volume patterns, suggests evolving market positioning and potential directional bets among traders."
      },
      {
        "title": "P/E at 22.91 vs Industry's 34.29: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-3984980",
        "imagepath": "",
        "date": "2026-05-11 09:20:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 22.91, markedly below the sector average of 34.29. This 33.2% discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. The pharmaceutical sector often commands premium valuations due to steady earnings and defensive characteristics, so this gap raises questions about the underlying fundamentals or market sentiment. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s valuation discount could reflect concerns over recent earnings trends or competitive pressures, but it also i..."
      },
      {
        "title": "Cipla Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-sell-by-marketsmojo-3982823",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CiplaLtd_mojoScore_3982823.png",
        "date": "2026-05-09 10:10:14",
        "description": "Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "P/E at 23.12 vs Industry's 34.54: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-3981016",
        "imagepath": "",
        "date": "2026-05-08 09:20:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E of 23.12, substantially below the Pharmaceuticals &amp; Biotechnology industry average of 34.54. This 33% discount to the sector multiple suggests the market is pricing in either lower growth expectations or elevated risks relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, but <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> appears to be viewed more conservatively. This valuation gap invites the question <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">w..."
      },
      {
        "title": "P/E at 23.10 vs Industry's 34.48: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-institutional-shifts-and-sector-dynamics-3979151",
        "imagepath": "",
        "date": "2026-05-07 09:20:44",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premium</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 23.10, substantially below the Pharmaceuticals &amp; Biotechnology industry average of 34.48. This 33% discount suggests the market is pricing in either subdued growth expectations or risk factors not reflected in the broader sector valuation. The sector’s elevated P/E is supported by strong earnings growth and positive results from all seven companies that have declared so far this season, with zero flat or negative outcomes. This contrast raises the question of whether <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> is un..."
      },
      {
        "title": "P/E at 22.66 vs Industry's 33.83: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amidst-mixed-performance-and-institutional-shifts-3977231",
        "imagepath": "",
        "date": "2026-05-06 09:20:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 22.66, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 33.83. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable given the sector’s overall positive earnings momentum, with all six companies reporting results so far posting positive outcomes. The discount raises the question of whether <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> is undervalued or facing structural challenges ..."
      },
      {
        "title": "P/E at 22.68 vs Industry's 33.77: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-3975386",
        "imagepath": "",
        "date": "2026-05-05 09:20:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premiums</strong></p>\n                <p>The current P/E ratio of 22.68 for <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> stands well below the sector average of 33.77, indicating a substantial valuation discount. This divergence suggests the market is pricing in either company-specific challenges or a cautious outlook relative to peers. The sector’s elevated P/E reflects strong earnings growth expectations, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla</a> appears to be lagging in investor confidence despite its large-cap status and ₹1,07,673.39 crore market capitalisation. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-59714..."
      },
      {
        "title": "P/E at 22.3 vs Industry's 33.4: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-institutional-shifts-3973315",
        "imagepath": "",
        "date": "2026-05-04 10:30:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> currently trades at a P/E of 22.3, markedly below the Pharmaceuticals &amp; Biotechnology industry average of 33.4. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a gap is notable given the sector’s overall positive earnings momentum, with all three companies reporting results so far posting positive outcomes. The valuation gap raises the question <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">previously rated Hold, what is Cipla Ltd.'s current rating?</a> The premium..."
      }
    ],
    "total": 1035,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "details": "Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "09-Dec-2019"
    },
    {
      "details": "Cipla Limited has informed the Exchange that its wholly owned subsidiary Cipla (EU) Limited, holding 60% stake in Cipla Pharma Lanka (Private) Limited {Cipla Pharma Lanka), Sri Lanka, has signed an agreement with CitiHealth Imports",
      "source": "NSE",
      "caption": "Cipla Limited - Acquisition",
      "datetime": "28-Nov-2019"
    },
    {
      "details": "Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "21-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "13 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 27 Jun 25",
          "dt": "2025-06-27",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cipla Ltd. Hits Intraday Low Amid Price Pressure on 11 May 2026

2026-05-11 15:15:58

Cipla Ltd. experienced a notable decline today, touching an intraday low of Rs 1305.4, reflecting a 3.14% drop as the stock faced significant price pressure amid broader market weakness and sector underperformance.

Read full news article

Cipla Ltd Sees Sharp Open Interest Surge Amidst Weak Price Action

2026-05-11 15:00:08

Cipla Ltd., a leading large-cap pharmaceutical stock, has witnessed a notable 10.18% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in open interest, coupled with declining prices and volume patterns, suggests evolving market positioning and potential directional bets among traders.

Read full news article

P/E at 22.91 vs Industry's 34.29: What the Data Shows for Cipla Ltd.

2026-05-11 09:20:40

Valuation Picture: Discount Amid Sector Premiums

Cipla Ltd. trades at a P/E multiple of 22.91, markedly below the sector average of 34.29. This 33.2% discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. The pharmaceutical sector often commands premium valuations due to steady earnings and defensive characteristics, so this gap raises questions about the underlying fundamentals or market sentiment. Cipla Ltd.’s valuation discount could reflect concerns over recent earnings trends or competitive pressures, but it also i...

Read full news article

Cipla Ltd. is Rated Sell by MarketsMOJO

2026-05-09 10:10:14

Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

P/E at 23.12 vs Industry's 34.54: What the Data Shows for Cipla Ltd.

2026-05-08 09:20:57

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. trades at a P/E of 23.12, substantially below the Pharmaceuticals & Biotechnology industry average of 34.54. This 33% discount to the sector multiple suggests the market is pricing in either lower growth expectations or elevated risks relative to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, but Cipla Ltd. appears to be viewed more conservatively. This valuation gap invites the question w...

Read full news article

P/E at 23.10 vs Industry's 34.48: What the Data Shows for Cipla Ltd.

2026-05-07 09:20:44

Valuation Picture: Discounted P/E Amid Sector Premium

Cipla Ltd. trades at a P/E multiple of 23.10, substantially below the Pharmaceuticals & Biotechnology industry average of 34.48. This 33% discount suggests the market is pricing in either subdued growth expectations or risk factors not reflected in the broader sector valuation. The sector’s elevated P/E is supported by strong earnings growth and positive results from all seven companies that have declared so far this season, with zero flat or negative outcomes. This contrast raises the question of whether Cipla Ltd. is un...

Read full news article

P/E at 22.66 vs Industry's 33.83: What the Data Shows for Cipla Ltd.

2026-05-06 09:20:51

Valuation Picture: Discount Amid Sector Premiums

Cipla Ltd. trades at a P/E multiple of 22.66, markedly below the Pharmaceuticals & Biotechnology industry average of 33.83. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable given the sector’s overall positive earnings momentum, with all six companies reporting results so far posting positive outcomes. The discount raises the question of whether Cipla Ltd. is undervalued or facing structural challenges ...

Read full news article

P/E at 22.68 vs Industry's 33.77: What the Data Shows for Cipla Ltd.

2026-05-05 09:20:37

Valuation Picture: Discounted P/E Amid Sector Premiums

The current P/E ratio of 22.68 for Cipla Ltd. stands well below the sector average of 33.77, indicating a substantial valuation discount. This divergence suggests the market is pricing in either company-specific challenges or a cautious outlook relative to peers. The sector’s elevated P/E reflects strong earnings growth expectations, yet Cipla appears to be lagging in investor confidence despite its large-cap status and ₹1,07,673.39 crore market capitalisation. Read full news article

P/E at 22.3 vs Industry's 33.4: What the Data Shows for Cipla Ltd.

2026-05-04 10:30:31

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. currently trades at a P/E of 22.3, markedly below the Pharmaceuticals & Biotechnology industry average of 33.4. This 33% discount to sector valuation suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a gap is notable given the sector’s overall positive earnings momentum, with all three companies reporting results so far posting positive outcomes. The valuation gap raises the question previously rated Hold, what is Cipla Ltd.'s current rating? The premium...

Read full news article

View All News